Johan S Bakken

Summary

Publications

  1. ncbi Human granulocytic anaplasmosis
    Johan S Bakken
    Department of Family Medicine, University of Minnesota Duluth, School of Medicine, 1001 E Superior Street, Suite L201, Duluth, MN 55202, USA
    Infect Dis Clin North Am 22:433-48, viii. 2008
  2. ncbi Clinical diagnosis and treatment of human granulocytotropic anaplasmosis
    Johan S Bakken
    St Luke s Infectious Disease Associates, 1001 East First Street, Suite L201, Duluth, Minnesota 55802, USA
    Ann N Y Acad Sci 1078:236-47. 2006
  3. ncbi The fluoroquinolones: how long will their utility last?
    Johan S Bakken
    St Luke s Infectious Disease Associates, Duluth, Minnesota 55805, USA
    Scand J Infect Dis 36:85-92. 2004
  4. ncbi The serological response of patients infected with the agent of human granulocytic ehrlichiosis
    Johan S Bakken
    Section of Infectious Diseases, St Mary Duluth Clinic Health System, Duluth, MN 55805, USA
    Clin Infect Dis 34:22-7. 2002
  5. ncbi Treating Clostridium difficile infection with fecal microbiota transplantation
    Johan S Bakken
    St Luke s Infectious Disease Associates, Duluth, Minnesota, USA
    Clin Gastroenterol Hepatol 9:1044-9. 2011
  6. ncbi Resolution of recurrent Clostridium difficile-associated diarrhea using staggered antibiotic withdrawal and kefir
    Johan S Bakken
    Section of Infectious Disease, St Luke s Medical Center, Duluth, USA
    Minn Med 92:38-40. 2009
  7. ncbi The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America
    Gary P Wormser
    Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Clin Infect Dis 43:1089-134. 2006
  8. ncbi Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States
    Max Maurin
    , , , Marseille, France
    Antimicrob Agents Chemother 47:413-5. 2003
  9. ncbi Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment
    J Stephen Dumler
    Division of Medical Microbiology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Clin Infect Dis 45:S45-51. 2007
  10. ncbi Human granulocytic anaplasmosis and macrophage activation
    J Stephen Dumler
    Division of Medical Microbiology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Clin Infect Dis 45:199-204. 2007

Collaborators

Detail Information

Publications16

  1. ncbi Human granulocytic anaplasmosis
    Johan S Bakken
    Department of Family Medicine, University of Minnesota Duluth, School of Medicine, 1001 E Superior Street, Suite L201, Duluth, MN 55202, USA
    Infect Dis Clin North Am 22:433-48, viii. 2008
    ..This article focuses on the diagnosis and management of human granulocytic anaplasmosis (HGA) caused by Anaplasma phagocytophilum...
  2. ncbi Clinical diagnosis and treatment of human granulocytotropic anaplasmosis
    Johan S Bakken
    St Luke s Infectious Disease Associates, 1001 East First Street, Suite L201, Duluth, Minnesota 55802, USA
    Ann N Y Acad Sci 1078:236-47. 2006
    ..Thus, prompt institution of antibiotic therapy is advocated for any patient who is suspected to have HGA and for all patients who have confirmed HGA...
  3. ncbi The fluoroquinolones: how long will their utility last?
    Johan S Bakken
    St Luke s Infectious Disease Associates, Duluth, Minnesota 55805, USA
    Scand J Infect Dis 36:85-92. 2004
    ..Fluoroquinolone resistance relates directly to human and veterinary usage and emerging bacterial resistance poses the single greatest threat to the future survival of the fluoroquinolone drugs as an antibiotic class...
  4. ncbi The serological response of patients infected with the agent of human granulocytic ehrlichiosis
    Johan S Bakken
    Section of Infectious Diseases, St Mary Duluth Clinic Health System, Duluth, MN 55805, USA
    Clin Infect Dis 34:22-7. 2002
    ..Indirect fluorescent antibody testing of acute-phase and convalescent-phase serum samples is a sensitive tool for laboratory confirmation of HGE...
  5. ncbi Treating Clostridium difficile infection with fecal microbiota transplantation
    Johan S Bakken
    St Luke s Infectious Disease Associates, Duluth, Minnesota, USA
    Clin Gastroenterol Hepatol 9:1044-9. 2011
    ..Fecal microbiota transplantation is safe, inexpensive, and effective; according to case and small series reports, about 90% of patients are cured. We discuss the rationale, methods, and use of fecal microbiota transplantation...
  6. ncbi Resolution of recurrent Clostridium difficile-associated diarrhea using staggered antibiotic withdrawal and kefir
    Johan S Bakken
    Section of Infectious Disease, St Luke s Medical Center, Duluth, USA
    Minn Med 92:38-40. 2009
    ..Further studies will be needed to determine whether gradual antibiotic withdrawal combined with kefir is a valuable treatment for recurrent C. difficile-associated diarrhea...
  7. ncbi The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America
    Gary P Wormser
    Division of Infectious Diseases, Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Clin Infect Dis 43:1089-134. 2006
    ..Tables list the doses and durations of antimicrobial therapy recommended for treatment and prevention of Lyme disease and provide a partial list of therapies to be avoided. A definition of post-Lyme disease syndrome is proposed...
  8. ncbi Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States
    Max Maurin
    , , , Marseille, France
    Antimicrob Agents Chemother 47:413-5. 2003
    ..The results are homogeneous and show that doxycycline, rifampin, and levofloxacin are the most active antibiotics against these strains in vitro...
  9. ncbi Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment
    J Stephen Dumler
    Division of Medical Microbiology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Clin Infect Dis 45:S45-51. 2007
    ....
  10. ncbi Human granulocytic anaplasmosis and macrophage activation
    J Stephen Dumler
    Division of Medical Microbiology, Department of Pathology, The Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    Clin Infect Dis 45:199-204. 2007
    ..Macrophage activation and excessive cytokine production may belie tissue injury associated with Ananplasma phagocytophilum infection...
  11. ncbi Successful treatment of human granulocytic ehrlichiosis in children using rifampin
    Peter J Krause
    Department of Pediatrics, University of Connecticut School of Medicine and Connecticut Children's Medical Center, Hartford, USA
    Pediatrics 112:e252-3. 2003
    ..A course of rifampin for 5 to 7 days should be considered in children younger than 8 years of age who experience non-life-threatening A phagocytophilum infection...
  12. ncbi Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals
    Alice S Chapman
    National Center for Infectious Diseases, CDC, Atlanta, GA 30333, USA
    MMWR Recomm Rep 55:1-27. 2006
    ....
  13. ncbi The value of an infectious diseases specialist
    Russell M Petrak
    Metro Infectious Disease Consultants, Hinsdale, Illinois 60521, USA
    Clin Infect Dis 36:1013-7. 2003
    ..This article summarizes the versatile attributes possessed by ID specialists and delineates their value to patients, hospitals, and other integral groups in the health care continuum...
  14. ncbi Dispelling the chronic Lyme disease myth
    Melissa M Kemperman
    Minnesota Department of Health, USA
    Minn Med 91:37-41. 2008
    ..If active infection with B. burgdorferi is unlikely, they should avoid prescribing empiric antibiotic therapy and instead thoroughly evaluate the patient for other possible causes of the complaints and recommend appropriate care...
  15. ncbi Human granulocytic anaplasmosis and Anaplasma phagocytophilum
    J Stephen Dumler
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Emerg Infect Dis 11:1828-34. 2005
    ..More study is needed to define the immunology and pathogenetic mechanisms and to understand why severe disease develops in some persons and why some animals become long-term permissive reservoir hosts...
  16. ncbi A case of Sweet syndrome associated with human granulocytic anaplasmosis
    Charles L G Halasz
    Department of Dermatology, Columbia University College of Physicians and Surgeons, New York, NY, USA
    Arch Dermatol 141:887-9. 2005
    ..CONCLUSION: The significant involvement of neutrophils with both SS and HGA warrants a broader search for additional cases that may further define whether pathogenetic linkages could exist...